MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.70
0.00
0.00%
Closed 16:00 11/19 EST
OPEN
8.72
PREV CLOSE
8.70
HIGH
8.91
LOW
8.61
VOLUME
862.60K
TURNOVER
--
52 WEEK HIGH
14.98
52 WEEK LOW
6.16
MARKET CAP
506.94M
P/E (TTM)
-9.4207
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CCXI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CCXI News

  • ChemoCentryx Option Alert: Dec 20 $10 Calls at the Ask: 3000 @ $2.451 vs 4676 OI; Ref=$8.745
  • Benzinga.19h ago
  • Edited Transcript of CCXI earnings conference call or presentation 4-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.3d ago
  • How Should Investors React To ChemoCentryx, Inc.'s (NASDAQ:CCXI) CEO Pay?
  • Simply Wall St..11/11 13:33
  • Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
  • GlobeNewswire.11/05 13:30

More

Industry

Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About CCXI

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
More

Webull offers ChemoCentryx Inc (CCXI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.